Weight-loss pharmacology has a history — and a cautionary one
From 2,4-Dinitrophenol (banned 1938) to Fen-Phen (withdrawn 1997) to lorcaserin (withdrawn 2020), the market has repeatedly seen effective drugs pulled for safety. Each withdrawal changed how regulators evaluate obesity medications — and why today's approvals demand cardiovascular outcome data.
| Medication Name | Biological Mechanism of Action | Reported Efficacy | Primary Safety / Adverse Events | Year of Withdrawal / Action Taken | Source |
|---|---|---|---|---|---|
| Lorcaserin (Belviq) | 5-HT2C receptor agonist | 3.3% to 6.25% (placebo-subtracted) | Increased risk of cancer | Withdrawn 2019/ | 2, 3, Inferred, Wikipedia Withdrawn Medications |
| Sibutramine (Meridia) | Serotonin–norepinephrine reuptake inhibitor | 4.3% to 19.7% (~4.3–4.5 kg / 9.5 lbs) | Cardiovascular events, including increased risk of heart attack and stroke | Withdrawn | 2, 3, 4, Inferred, Wikipedia Withdrawn Medications |
| Rimonabant (Acomplia) | Cannabinoid receptor (CB1) antagonist | 13.9% (2.6 to 6.3 kg / 5.7 to 13.9 lbs) | Severe psychiatric disturbances and suicide risks | Withdrawn 2008/ | 2, 3, Inferred, Wikipedia Withdrawn Medications |
| Fenfluramine / Phentermine (Fen-Phen) | Serotonergic releasing agent / Sympathomimetic amine | 13.9% to 15% (~15 to 17.1 lbs / 7.7 kg) | Valvular heart disease and pulmonary hypertension | Withdrawn | 2, 3, Inferred, Wikipedia Withdrawn Medications |
| 2,4-Dinitrophenol (DNP) | Mitochondrial uncoupling agent | Rapid weight loss (~1.5 kg per week / 17.1 lbs average) | Fatal hyperthermia, cataracts, and multi-organ failure | Banned | 2, 3, Inferred, Wikipedia Withdrawn Medications |
| Ephedra | Sympathomimetic (alpha and beta adrenergic agonist) | 0.6 to 0.9 kg (2.0 lbs) per month more than placebo | Cardiovascular events, stroke, seizures, and fatal outcomes | Banned | 2, 3, Inferred, Wikipedia Withdrawn Medications |
| Dexfenfluramine (Redux) | Serotonin releasing agent | 3.5 kg (7.7 lbs) | Valvular heart disease | Withdrawn | |
| Fenfluramine (Pondimin) | Serotonin releasing agent | Not in source | Valvular heart disease | Withdrawn | |
| Phenylpropanolamine | Not in source | 1.5 kg (3.3 lbs) | Risk of hemorrhagic stroke | Withdrawn | |
| Amphetamine salts (Obetrol) | Not in source | Not in source | Mental disturbances, cardiac side effects, and drug dependence | Withdrawn |
Why this history matters now
The modern GLP-1 generation was approved with cardiovascular-outcome trials — a direct response to the sibutramine and fenfluramine disasters. When you see a headline about a new weight-loss drug, this table is the context: efficacy was never the problem in the past; long-term safety was.
The short version
- The market has repeatedly pulled effective weight-loss drugs for safety, from 2,4-Dinitrophenol banned in 1938 to Fen-Phen withdrawn in 1997 and lorcaserin in 2020.
- Lorcaserin (Belviq), a 5-HT2C receptor agonist producing 3.3% to 6.25% placebo-subtracted loss, was withdrawn over an increased risk of cancer.
- Sibutramine (Meridia), a serotonin-norepinephrine reuptake inhibitor, was withdrawn over cardiovascular events including increased heart attack and stroke risk.
- Rimonabant (Acomplia), a CB1 antagonist producing 13.9% loss, was withdrawn in 2008 for severe psychiatric disturbances and suicide risk.
- Fen-Phen was withdrawn for valvular heart disease and pulmonary hypertension, and DNP was banned for fatal hyperthermia and multi-organ failure.
- The modern GLP-1 generation was approved with cardiovascular-outcome trials, a direct response to the sibutramine and fenfluramine disasters.
The practical takeaway
Use approved medications under medical supervision, report side effects, and treat "miracle" claims with the skepticism this history justifies. Get matched with a provider who follows the evidence — past and present.
